Letter to the Editor. Clazosentan was superior to placebo, but was the comparison appropriate?
- PMID: 36964737
- DOI: 10.3171/2023.1.JNS2316
Letter to the Editor. Clazosentan was superior to placebo, but was the comparison appropriate?
Comment on
-
Effects of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage: two randomized phase 3 trials in Japanese patients.J Neurosurg. 2022 Apr 1;137(6):1707-1717. doi: 10.3171/2022.2.JNS212914. Print 2022 Dec 1. J Neurosurg. 2022. PMID: 35364589 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
